SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458506073522v1
13/5/567    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Farrell, R. A
Right arrow Articles by Giovannoni, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farrell, R. A
Right arrow Articles by Giovannoni, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis

Rachel A Farrell

Department of Neuroimmunology, Institute of Neurology, London, UK

Gavin Giovannoni

Department of Neuroimmunology, Institute of Neurology, London, UK, g.goivannoni{at}ion.ucl.ac.uk

Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS. Multiple Sclerosis 2007; 13: 567-577. http://msj.sagepub.com

Key Words: Interferon-beta • neutralising antibody • biological treatment • bioassay • MxA bioassay • cytopathic effect assay

This version was published on June 1, 2007

Multiple Sclerosis, Vol. 13, No. 5, 567-577 (2007)
DOI: 10.1177/1352458506073522
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis
Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328.
[Abstract] [PDF]

Home page
 Mult SclerHome page
L. van der Voort, A Kok, A Visser, C. Oudejans, M Caldano, F Gilli, A Bertolotto, C. Polman, and J Killestein
Interferon-{beta} bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice
Multiple Sclerosis, February 1, 2009; 15(2): 212 - 218.
[Abstract] [PDF]

Home page
 Mult SclerHome page
A.R. Pachner
Neutralizing anti-IFN{beta} antibodies: clarity and confusion
Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082.
[PDF]


Advertisement